Search

This article discusses the importance of therapeutic adherence in patients treated with PCSK9 inhibitors for dyslipidemias and cardiovascular disease prevention. The article highlights the need for a holistic approach to reduce LDL cholesterol and cardiovascular risk in patients with heterozygous familial hypercholesterolemia. It also mentions the safety and effectiveness of PCSK9 inhibitors, but emphasizes the importance of monitoring for potential side effects such as mild hyperglycemia and injection-site reactions. The authors stress the need for clear communication between doctors and patients to ensure adherence to lipid-lowering therapy and the success of these expensive treatments. [Extracted from the article]